Best Practice & Research Clinical Endocrinology & Metabolism
5Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate
Section snippets
Phase-1 androgen metabolism: 3α-steroid dehydrogenase and 17β-steroid dehydrogenase, first step in the conversion of active to inactive androgens
The phase-1 inactivation of DHT (Figure 2) involves several possible pathways with the contribution of a 17β-HSD oxidative reaction (17β-HSD type 2) forming the 17-ketosteroid androstanedione and then the 3α-HSD type 3 reductive reaction forming androsterone (ADT), or the direct conversion of DHT via the same 3α-HSD to androstane-3α,17β-diol (3α-DIOL).8 The expression of 17β-HSD type 2 and 3α-HSD type 3 transcripts has been detected in all androgen target tissues studied so far. Using
Phase-2 enzymes: glucuronosyltransferase enzymes and complete inactivation of androgens
The glucuronidation reaction catalyzed by enzymes of the UGT superfamily corresponds to the transfer of the glucuronosyl group from UDP-glucuronic acid to small hydrophobic molecules.9 The resulting glucuronide products are more polar, generally water-soluble, less toxic, and more easily excreted from the body than is the parent compound. Based upon homology of primary structures, the UGT proteins have been categorized into two families, namely UGT1 and UGT2 (Figure 3).10
In humans, the UGT1A
Androgen glucuronides in the circulation
In humans, blood levels of non-conjugated 3α-DIOL and ADT, the two major metabolites of DHT, are below 1 ng/mL.17 Several observations published over the last 25 years clearly establish that a large portion of the androgen metabolites found in blood and urine are under the form of glucuronide derivatives.18, 19, 20, 21, *22 A liquid chromatographic/mass spectroscopic (LC-MS/MS) method for the determination in serum of 3α-diol-glucuronides and ADT-G was recently developed by our group; this
Expression of UGT2B enzymes in the prostate
The expression of UGT2B enzymes in the human prostate was studied in more detail by in situ hybridization and immunohistochemistry (Figure 4).16, *25 In the human prostate, the alveoli are composed of two epithelial cell types. The basal layer is composed of small cells located at the periphery of the alveoli, while the luminal cells are large columnar cells in contact with the alveolar lumen and lined above the continuous basal layer. The two cell types play distinct but complementary roles in
Modulation of UGT2B15/B17 gene expression and its impact on androgen concentrations and activity
Several studies using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry have demonstrated a large inter-individual variability in UGT expression in tissues including the breast, liver and gastrointestinal tract, thus suggesting that these enzymes are modulated by several factors. The presence of high glucuronidation activity in LNCaP cells, a human prostate cancer cell line, has led to the characterization of the UGT2B enzymes expressed in this cell
Polymorphism in the UGT2B15 gene and deletion of the UGT2B17 gene
In addition to the first UGT2B15(D85) isolated by Chen et al30, Levesque et al31 discovered a second form of UGT2B15, namely UGT2B15(Y85), and demonstrated that the Vmax for DHT conjugation of the Y allele is two-fold greater than the enzyme resulting from the D allele. It was then postulated that the high efficacy of the UGT2B15(Y85) enzyme in the prostate may protect the tissue from high levels of DHT and decrease the risk of prostate cancer. In 2000, MacLeod et al32 were the first to
Conclusion
In this review, the metabolism of androgens – particularly the conversion of androgens to androgen glucuronides – has been discussed. The fine regulation of the intracellular concentration of androgens in the prostate is ensured not only at the level of activation by steroidogenic enzymes but also at the level of degradation by steroid-inactivating enzymes. Two members of the UGT2B enzymes, UGT2B15/B17, are expressed in the prostate, and changes in their activity may influence the
References (40)
- et al.
The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate
The Journal of Biological Chemistry
(1968) - et al.
Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans
Trends in Endocrinology and Metabolism
(2003) - et al.
Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4
Journal of Molecular Biology
(2000) - et al.
Physiopathology of plasma androstanediol-glucuronide
The Journal of Steroid Biochemistry and Molecular Biology
(1991) - et al.
Increase in plasma 5 alpha-androstane-3 alpha,17 beta-diol glucuronide as a marker of peripheral androgen action in hirsutism: a side-effect induced by cyclosporine A
Journal of Steroid Biochemistry
(1990) - et al.
Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women
The Journal of Steroid Biochemistry and Molecular Biology
(2006) - et al.
Characterization of UDP-glucuronosyltransferases active on steroid hormones
The Journal of Steroid Biochemistry and Molecular Biology
(1999) - et al.
Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP
The Journal of Steroid Biochemistry and Molecular Biology
(1996) - et al.
UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells
The Journal of Biological Chemistry
(2007) - et al.
Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer
The Journal of Urology
(2004)
Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population
Cancer Detection and Prevention
Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk
Urology
The UGT2B17 gene deletion polymorphism and risk of prostate cancer A case-control study in Caucasians
Cancer Detection and Prevention
I. The results of double castration in hypertrophy of the prostate
Annals of Surgery
The artificial preparation of the male sex hormone
Current Science
Endocrine control of prostatic cancer
Science
Cancer of the prostate
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen
Clinical and Investigative Medicine
Is dehydroepiandrosterone a hormone?
The Journal of Endocrinolology
Cited by (70)
Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia
2022, Journal of Steroid Biochemistry and Molecular BiologyInsight into tartrate inhibition patterns in vitro and in vivo based on cocrystal structure with UDP-glucuronosyltransferase 2B15
2020, Biochemical PharmacologyCitation Excerpt :Also, it is a vital regulator of the concentrations of nuclear receptor ligands [12]. For instance, the level of androgen receptor ligands is affected by UGT2B15 and UGT2B17 [13–15]. Above all, glucuronidation balance of UGT2B15 is relevant to some diseases, and a series of toxicological or disorder events might occur due to the inhibition of the glucuronidation in vivo [16].
Steroid Hormones and Other Lipid Molecules Involved in Human Reproduction
2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth EditionLoss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging
2018, Journal of Biological ChemistryCitation Excerpt :This results in a marked prolongation of cellular exposure to DHT in media (Fig. 1B) and as well as in the intracellular space (Fig. 1C). UGT2B15 and UGT2B17 are the 2 major enzymes that are responsible for androgen glucuronidation in prostate cancer (10, 14). The transition from LNCaP to the resistant C4-2 model is accompanied by a profound loss of expression of the glucuronidation machinery (Fig. 1, D and E), which accounts for the apparent switch in metabolic phenotype (Fig. 1A).
Intracrine androgen biosynthesis, metabolism and action revisited
2018, Molecular and Cellular Endocrinology